Brief: Transgene Raises Around EUR 34.1 Mln

Transgene SA

22/06/2021 06:07

June 22 (Reuters) - TRANSGENE SA  TRNG.PA :
    * TRANSGENE ANNOUNCES THE SUCCESS OF ITS CAPITAL INCREASE
VIA A
PRIVATE PLACEMENT
    * SUCCESSFUL CAPITAL INCREASE THROUGH A PRIVATE PLACEMENT
VIA AN
ACCELERATED BOOKBUILDING FOR AN AMOUNT OF APPROXIMATELY 34.1
MILLION EUROS
    * FUNDS WILL BE DIRECTLY USED BY DESCENDING ORDER OF
STRATEGIC
PRIORITY: CIRCA EUR 25M FOR FINALIZATION OF CLINICAL STUDIES AND
OBTENTION OF DATA WITH TG4001, TG4050, BT-001 AND TG6002
    * CAPITAL INCREASE RESULTS IN ISSUANCE OF 13,930,000 NEW
ORDINARY
SHARES AT A SUBSCRIPTION PRICE OF 2.45 EUROS (INCLUDING ISSUE
PREMIUM), REPRESENTING 16,6 % OF CURRENT SHARE CAPITAL OF
COMPANY
    * FUNDS WILL BE DIRECTLY USED BY DESCENDING ORDER OF
STRATEGIC
PRIORITY: CIRCA EUR 4M TO LAUNCH CLINICAL DEVELOPMENT OF NEW
ONCOLYTIC VIRUSES BASED ON INVIR.IO PLATFORM AND CURRENTLY
UNDERGOING PRECLINICAL EVALUATION
    * SUBSCRIPTION PRICE REPRESENTS A DISCOUNT OF 6.5% COMPARED
TO
CLOSING PRICE OF TRANSGENE ON JUNE 21, 2021 (EUR 2.62)
    * TRANSACTION WILL BE CARRIED OUT UNDER 22ND RESOLUTION OF
COMBINED GENERAL SHAREHOLDERS' MEETING OF MAY 27, 2020
    * THE FUNDS RAISED IN THE CAPITAL INCREASE WILL BE USED TO
STRENGTHEN THE COMPANY'S FINANCIAL STRUCTURE UNTIL THE FOURTH
QUARTER OF 2023

Source text for Eikon:  ID:nBwby5b1Ya 
Further company coverage:  TRNG.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))